No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SDGR240719P30000
- 7.45
- 0.000.00%
15min DelayClose Jun 7 10:58 ET
0.00High0.00Low
0.00Open7.45Pre Close0 Volume0 Open Interest30.00Strike Price0.00Turnover2884.96%IV2.84%PremiumJul 19, 2024Expiry Date6.79Intrinsic Value100Multiplier-2DDays to Expiry0.66Extrinsic Value100Contract SizeAmericanOptions Type-0.8505Delta0.0379Gamma3.12Leverage Ratio-19.5332Theta0.0000Rho-2.65Eff Leverage0.0005Vega
Intraday
- 5D
- Daily
News
Express News | Schrodinger Inc : BMO Cuts Target Price to $30 From $36
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2024 financial results on Wednesday, July 31, 2024,
What Analysts Are Saying About Schrodinger Stock
During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent
KeyBanc Maintains Schrodinger(SDGR.US) With Buy Rating, Cuts Target Price to $25
KeyBanc analyst Scott Schoenhaus maintains $Schrodinger(SDGR.US)$ with a buy rating, and adjusts the target price from $33 to $25.According to TipRanks data, the analyst has a success rate of 31.9%
Schrodinger Is Maintained at Overweight by Keybanc
Schrodinger Is Maintained at Overweight by
Express News | Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $25
Comments
$Schrodinger(SDGR.US$ i have been saying this for days and weeks now but if you're looking for a time to buy small caps now is the time it's still not too late these small caps have massive price gaps they need to fill they'll be forming giant cup and handles and many of them have been bottoming for the longest time while the mag7 were carrying the whole SPY & QQQ
they just needed a catalyst from rate cuts and this expectation is enough to tr...
they just needed a catalyst from rate cuts and this expectation is enough to tr...
7
$Schrodinger(SDGR.US$ this stock has been disappointing but there are signs of reversal
I'm not intending to trade this stock but meant to hold long term at least 1 year horizon but probably more. extremely bullish on AI driven drug discovery
just need to find a good entry price
I'm not intending to trade this stock but meant to hold long term at least 1 year horizon but probably more. extremely bullish on AI driven drug discovery
just need to find a good entry price
4
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
Read more